Glaucoma is an ocular condition characterized by elevated intraocular pressure (IOP). Conventional treatments of glaucoma face poor corneal permeability and bioavailability. To address these issues, a nanoemulsion in situ gel of Timolol maleate was developed in this study by adding the polymer Carbopol 934p. Using Carbopol 934p, a novel ophthalmic pH-induced nanoemulsion in situ gel was formulated. The formulation was liquid at pH 4 and quickly gelled when the pH was raised to 7.4 (Lacrimal pH). The pH-triggered in situ gelling mechanism demonstrated continuous drug release over a 24 h cycle. A total of nine trial formulations were prepared (NEI₁–NEI₉) and subjected to various physicochemical and in vitro evaluations. According to the in vitro release kinetics, the drug release of Timolol maleate nanoemulsion in situ gel NEI₅ followed zero-order kinetics, with a release exponent value of 0.902, indicating that the mechanism of release was non-Fickian diffusion regulated. In vivo results showed that Timolol maleate nanoemulsion in situ gel NEI₅ provided a better-sustained release of the drug, compared with the Timolet OD eye drops. The formulation is stable in storage, with no distinguishable change in appearance, physical properties, quality, and percentage drug release. NEI₅ also reduces drug administration frequency, which improves patient compliance. Timolol maleate nanoemulsion in situ gel NEI₅ achieved the goal of controlled drug delivery with extended-release and cost-effectiveness, lowering the dosage and frequency of drug administration, and thus may improve patient compliance. In conclusion, the stable nanoemulsion in situ gel of Timolol maleate NEI₅ decreases intraocular pressure (IOP) over a prolonged period.

The recent global resurgence of Mpox (formerly monkeypox), primarily transmitted via close contact and respiratory droplets, highlights a significant shift in its epidemiology, particularly among men who have sex with men (MSM). This resurgence underscores the need for robust public health responses and improved surveillance. This comprehensive review of current literature focuses on recent outbreaks, virology, and available treatments. Epidemiological data were gathered from various international health reports and analysed to understand transmission dynamics and outbreak patterns. Mpox, characterised by symptoms like fever and rash, has shown variable clinical presentations, particularly among immunocompromised individuals. Recent outbreaks have prompted the development of new diagnostic methods and treatments, including antivirals like Tecovirimat and vaccines such as MVA-BN. Studies have demonstrated the effectiveness of these vaccines in preventing infection, which is crucial for outbreak containment. The global response to the Mpox resurgence requires integrated strategies combining vaccination, antiviral treatments, and public health policies tailored to high-risk populations. Future efforts should focus on vaccine distribution equity and enhancing diagnostic capabilities to effectively manage and mitigate the impact of Mpox.

Oropouche fever, caused by the Oropouche virus (OROV), has become a significant public health concern. Recent outbreaks highlight its increasing global spread, driven by environmental, social, and ecological factors. The disease presents clinical similarities to other arboviral infections, making accurate diagnosis essential for effective management and prevention. This article examines the epidemiological patterns of Oropouche fever, including its geographic distribution and outbreak drivers. It explores the clinical manifestations of the disease, focusing on common symptoms, complications such as fatal cases and fetal abnormalities, and the necessity of differential diagnosis. The pathophysiology of OROV infection is analyzed, detailing viral entry mechanisms, immune responses, and the role of vectors in transmission. Additionally, we assess diagnostic challenges, comparing serological and molecular methods while identifying their limitations. Therapeutic strategies are also reviewed, including symptomatic treatments and potential antiviral candidates. Findings indicate that OROV infections mimic other arboviral diseases, complicating clinical diagnosis. Current diagnostic tools have limitations in accuracy and accessibility, particularly in resource-limited settings. Symptomatic treatment remains the primary approach, as no specific antiviral therapies or vaccines exist. The study identifies gaps in diagnostic development, vaccine research, and public health surveillance. Oropouche fever threatens global health, necessitating improved surveillance, diagnostic tools, and targeted research efforts. Enhancing epidemiological studies and developing effective vaccines will mitigate its impact. Strengthening public health strategies can help control the spread of OROV and reduce its burden on affected populations.

Contemporary patient care requires a multidisciplinary approach to monitoring, assessing, and managing diseases. Promoting multidisciplinary approaches encourages the purposeful participation of many healthcare professionals and harnessing their combined knowledge to provide tailored treatment plans. Pharmacists, skilled and knowledgeable professionals in medication management, drug-related problems, and disease prevention, can offer vital interventions that contribute to improved patient outcomes. Advances in healthcare and information technology have expanded pharmacists' professional roles and made them essential in healthcare. Pharmacist-managed clinics (PMCs), an innovative healthcare approach, could potentially improve patient safety, satisfaction, accessibility, and affordability to quality healthcare. Spread across the healthcare continuum, pharmacists have a well-defined role in providing comprehensive pharmaceutical care and interprofessional collaboration, further reinforcing the necessity of establishing PMCs. This narrative review aims to compile and summarize information on PMCs from PubMed, Scopus, Web of Science, and Google Scholar till December 2023. The PMC shortlist covers specialties such as cardiovascular, hematologic, endocrine, pain medicine, respiratory medicine, infectious diseases, gastrointestinal, nephrology, neurology, and oncology. Pharmacists in disease-specific PMCs have demonstrated improved treatment outcomes and access to specialty care. Additionally, based on peer-reviewed literature, the review also highlights how PMCs enhance the pharmacist's role in improving disease-specific outcomes, overall quality of care, and medication management. The inclusion criteria are randomized controlled trials, case-control studies, cohort studies, and pre-post studies involving patients from cardiology, hematology, endocrinology, pain medicine, respiratory medicine, infectious diseases, neurology, nephrology, gastroenterology, and oncology specialties, focusing on pharmacist-driven clinics, published in English, and covering any geographical location. The exclusion criteria include review articles, proposed models, commentaries, editorials, and those published in languages other than English. Our findings reveal that PMCs are underutilized globally. PMCs work better in developed countries, possibly on account of robust healthcare infrastructure, adequate healthcare budgets, availability of trained pharmacists, and supportive regulatory environments. The review found that pharmacist-led interventions, such as medication monitoring and patient education, significantly enhance therapeutic outcomes. Pharmacist Managed Clinics improve affordability and acceptability, expanding healthcare access in outpatient and inpatient settings. This review also highlights the critical need for implementing PMCs to improve healthcare delivery, particularly in providing comprehensive and accessible services in developing countries.

• Fever, headache, myalgia, and photophobia are common; severe cases include meningitis and encephalitis. • OROV can pass from mother to fetus, causing issues like microcephaly and stillbirths. • Up to 70% of patients report recurring symptoms like headache and fatigue after initial recovery. • Live attenuated vaccine candidate demonstrated safety and immunity in clinical trials. • Real-time RT-PCR detects OROV with 93% efficacy during the acute phase within five days of symptom onset. • Two deaths were reported in Bahia, Brazil, in 2024, marking the first confirmed OROV-related fatalities.

The recent outbreak of Monkeypox (Mpox), particularly the clade 1b variant, have shifted the epidemiological landscape, making it a Public Health Emergency of International Concern. Africa remains a hotspot with significant ongoing outbreaks, necessitating a focused study on outbreak trends and forecasting to guide health interventions. This study utilizes a comprehensive dataset from the four most affected African countries, covering weekly and cumulative Mpox cases from August 6, 2023, to August 18, 2024. Time series analysis techniques, including ARIMA models and Join Point Regression, were employed to forecast Mpox trends and analyse the annual percentage change in new cases. Descriptive statistics highlighted significant variability in Mpox cases across the studied regions with the mean cases in Africa at 72.55 and a high standard deviation of 60.885. Forecasting models suggest a continued increase in Mpox cases, with cumulative cases expected to reach 6922.95 by the 65th week (95 % CI: 6158.62 to 7687.27) and new cases projected at 45.93 (95 % CI: −88.17 to 180.04). The study underscores the persistent nature of Mpox outbreaks in Africa and the critical need for continuous surveillance and adaptive public health strategies. The forecasts generated offer valuable insights into potential future trends, aiding in the allocation of resources and the implementation of targeted health interventions to curb the spread of the disease.